Vilon vs Cartalax
Side-by-side comparison of Vilon and Cartalax: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Vilon
Cartalax
Vilon
Vilon is the simplest member of Vladimir Khavinson's short-peptide bioregulator catalog — a dipeptide of lysine and glutamic acid (H-Lys-Glu-OH, abbreviated KE). Developed at the Saint Petersburg Institute of…
No vendor price on file.
Full Vilon profileCartalax
Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to…
Lowest listed price: $58.85 across 3 listings
Full Cartalax profileSide-by-side comparison
| Attribute | Vilon | Cartalax |
|---|---|---|
| Category | Recovery | Recovery |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Vilon's proposed mechanism follows the Khavinson three-stage framework applied to the simplest-possible peptide. Stage one is absorption: oral Vilon is claimed to be absorbed intact from the gut because it is small enough (275 Da) to cross the intestinal… | Mechanism of Action Cartalax's proposed mechanism is the Khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing chondrocyte-favourable transcriptional shifts.… |
| Half-Life | Not established in humans; as a dipeptide (Lys-Glu) it is expected to be cleared from plasma within minutes, with proposed effects attributed to transient gene-expression modulation rather than sustained blood levels. | No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. |
| Typical Dose Range | 20 mg oral capsule (~2-4 mg Lys-Glu peptide), 1-2 capsules daily for 10 consecutive days per cycle | 20 mg oral/sublingual once daily for 10 days; 60-90 day washout |
| Dosing Frequency | — | Once daily |
| Administration | — | — |
| Side Effects | Published Khavinson-group observations describe Vilon as exceptionally well tolerated at oral doses of 1 to 2 capsules daily during 10-day cycles. The structural simplicity of the dipeptide — lysine and glutamate, both ubiquitous amino acids — and the low… | Side Effects and Safety Cartalax has been used in Russian clinical settings for roughly 20 years with a sparse adverse-event literature — reassuring in direction, insufficient for confident pharmacovigilance. Reported short-term adverse effects -… |
| Molecular Weight | 275.3 Da (C11H21N3O5) | 333.29 g/mol |
| Common Vial Sizes | — | — |
Price History
3 data points- Ion Peptide
- Disguised Alpha
- LB
Vilon: potential benefits
- Immune system support
- Tissue repair enhancement
- Anti-aging immune modulation
- General health optimization
Cartalax: potential benefits
- Joint and cartilage repair support
- Connective tissue maintenance
- Anti-aging effects on musculoskeletal system
- Improved joint mobility
Frequently asked
What's the difference between Vilon and Cartalax?
Vilon is a recovery that vilon's proposed mechanism follows the khavinson three-stage framework applied to the simplest-possible peptide. stage one is absorption: oral vilon is claimed to be absorbed…. Cartalax is a recovery that mechanism of action cartalax's proposed mechanism is the khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective…. The two differ in mechanism, half-life (Not established in humans; as a dipeptide (Lys-Glu) it is expected to be cleared from plasma within minutes, with proposed effects attributed to transient gene-expression modulation rather than sustained blood levels. vs No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured.), and typical dose range.
Which has the longer half-life, Vilon or Cartalax?
Vilon has a half-life of Not established in humans; as a dipeptide (Lys-Glu) it is expected to be cleared from plasma within minutes, with proposed effects attributed to transient gene-expression modulation rather than sustained blood levels.. Cartalax has a half-life of No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Vilon and Cartalax?
Stacking depends on mechanism overlap, safety profile, and goals. Vilon and Cartalax should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Vilon or Cartalax
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.